Lumida
/ALDX
⌘K
Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

ALDX
$1.34USD↓-8.22%-0.12 today

MARKET CAP

80.8M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$6

AI Summary

Stalk
StalkMedium

ALDX remains in an early/fragile Stage 1 consolidation base with accumulation signals from follow-through and exhaustion tags. Medium-term bias is bullish given the flattening 9/21 EMA regime and bottoming patterns, but price recently extended into resistance and is now pulling back. Short-term timing is neutral, so execution is deferred—stalking for pullbacks into the 9/21 EMA support zone.

  • ↑Phase III Reproxilab trial achieved p=0.002 reduction in ocular discomfort.
  • ↑Cash and marketable securities totaled $174.3M as of Dec 31, covering expenses until mid-2024.
  • ↓Net loss of $62M in 2022 increased from $57.8M prior year.
Full analysis →

Buying

6

institutions

Selling

2

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
AC

Aqr Capital Management LLC

Q2 2026

BUY3.75 M7.99 M+921.68 K+67.1%0.00%
BI

Blackrock, Inc.

Q2 2026

SELL1.26 M2.68 M+-2.51 M-57.9%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUY882.00 K1.88 M+18.81 K+28.8%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY542.74 K1.16 M+125.90 K+64.1%0.00%
MM

Millennium Management LLC

Q2 2026

SELL360.35 K767.55 K+-634.89 K-54.4%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

BUYNEW154.41 K328.89 K+154.41 K+0.0%0.00%
MG

Man Group Plc

Q2 2026

BUYNEW152.71 K325.28 K+152.71 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY109.58 K224.63 K+86.42 K+477.4%0.00%